VirtualScopics Inc

VirtualScopics — Shareholder Meeting (May 2011)

42 slides from VirtualScopics's shareholder meeting presentation, May 24, 2011

  1. Slide 1: Annual Stockholders' Meeting

    a ¥ VIRTUALSCOPICS | Annual Stockholders’ Meeting W, 4 May 24, 2011

  2. Slide 2: Presentation Overview

    Presentation Overview L # Vint ALScOPICS

  3. Slide 3: Meeting agenda: director election and auditor ratification

    Dan Kerpelman Robert Klimasewski Norman Mintz Charles Ph Terence We atify the appointment of Marcum LLP as independent financial statement auditors for the fiscal year ended December 31, 2011 OMT RTUALSCOPICS Brow mere Moe fv

  4. Slide 4: Presentation Overview

    Presentation Overview L # Vint ALScOPICS

  5. Slide 5: Safe Harbor

    3 SAFEHARBOR oO iT] This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance,

  6. Slide 6: Building for the Future: Company and Strategic Overview

    Building for the Future Company and Strategic Overview Jeff Markin President and CEO Molly Henderson Chief Business and Financial Officer

  7. Slide 7: Focus for today's discussion

    Focus for today’s discussion Jeff Markin, Chief Executive Officer -— * About VirtualScopics * Foundation built for success * Building for the future + 2011 Imperatives Molly Henderson, Chief Business & Financial Officer * Financial review * Personalized medicine application overview * Financial mark

  8. Slide 8: Company Mission

    Company Mission Oo Vv Our mission is to improve the lives of those impacted by disease and disability ————E a e VIRTUALSCOPICS

  9. Slide 9: VirtualScopics

    VirtualScopics VirtualScopics is a leading provider of quantitative imaging for clinical trials | Key Company Highlights. * Integrated solution delivered as a series of services that manage imaging trials from inception to FDA submission. + Highly automated quantitative analysis vs. conventional qua

  10. Slide 10: Therapeutic Areas

    Therapeutic Areas a O | AA Oey Vasc Partin (OCEMRL OCCT) Central Nervous System PAG Voume, ra preenyral Factor Peer that inure orgie

  11. Slide 11: Core Competencies

    Core Competencies quantify change in biological structures and processes through the use of medical imaging and imaging science To manage and process very large quantities of information quickly and efficiently in a flexible and transparent manner ‘ a VIRTUALSCOPICS

  12. Slide 12: Expertise in imaging systems and science

    Expertise in imaging systems and Imaging protocol design Expertise in image acquisition ‘quality control Imaging Science Expertise in image-based biomarkers. InOA, RA, oncology.cte. | Blomarker relevance to disease ‘progression Software Medicine Image Analy: a Se. ¥ VIRTUALSCOPICS

  13. Slide 13: Benefits: reduced subjects, accelerated time to market

    Reduced number of subjects + Higher precision = fewer patients + Fewer patients = lower trial costs Accelerated time to market + Smaller trial sizes = quicker enrollment and faster sults, + Algorithm driven analysis yields results faster than radiologists driven analysis Better information for Go-No

  14. Slide 14: Strong foundation to build upon!

    Strong foundation to build upon! A Study Experience | Financial Strength Employment & Leadership ¥ VIRTUALSCOPICS

  15. Slide 15: Study Experience

    Study Experience Phase1 Phase2 Phase3 Phase 4 Greater than half the studies we have conducted are Phase 2/3

  16. Slide 16: Financial Strength

    Financial Strength Revenue — 400% Increase over 4 years | Gross profit — 400% increase over 4 ars Adjusted EBITDA (Cash) positive ; q P : Self sustaining growing Business!! q ViealScopes At Rights Reserved ‘VIRTUALSCOPICS

  17. Slide 17: PPD Alliance

    PPD Alliance ter ‘cost efficiencies. ‘The partnership will provide seamless integration of technologies and processes, giving biopharmaceutical companies near real-time, consistent and reliable medical imaging information to expedite their drug development programs + “You definitely convinced me” fo

  18. Slide 18: Personalized Medicine

    Personalized Medicine ig | get an early look at the effectiveness of a patient’s treatment program. pre IDE application and anticipate 510K approval during 2011. ViealScopes At Rights Reserved

  19. Slide 19: Employee growth

    94 employees, 29% increase over 2010 terma ew employees * Building and accelerating [MM * CEO, CBFO, CTO, CSO, quality and efficiency Software, Regulatory VIRTUALSCOPICS VieualScopes At Rights Reserved

  20. Slide 20: 2011 Imperatives

    2011 Imperatives Meet Financial Goals Expansion of PPD Alli " ane Progress Personalized ea —— Imperatives Medicine Deliver Infrastructure and Technology Investments ima ¥ VIRTUALSCOPICS tive et

  21. Slide 21: Financial & Strategic Overview

    Financial & Strategic Overview a ¥ VIRTUALSCOPICS javelin FEN Molly Henderson ~~ Chief Business & Financial Officer, : Sr. Vice President

  22. Slide 22: 2010 Financial Guidance vs. Actual

    2010 Financial Guidance vs. Actual Beginning of Year Guidance | Revenues $13 million | $13.4 million | Full year gross margin 50% | 51% | Full year Adjusted EBITDA. | cen $1.5 million $2.2 million + 22% increase in full ar + Adjusted EBITDA of $2.2MM compared to $1.3MM in 2009 + $1.2 milion in cash

  23. Slide 23: Revenues & Gross Profit — Yearly Trends

    Revenues & Gross Profit — Yearly Trends AA Annual Revenues Annual Gross Profit 4x increase inf] Since inception in gross profit in 4 2001, over years, > 1005 $90MM and 270 increase in 2 years um increase in 2 years projects Steady growth in revenues and Bross profit ¥u RTUALSCOPICS sow ore Move fe:

  24. Slide 24: Revenue composition

    Revenue composition L Revenues by Study Phase revenues Mf Malorty of 2009- IM Musculoseletal inereasing revenues HA 010 growth ariven revenues due oe » by Phase III studies reduction in R&D spending by Pharma Significant growth in Oncology business since 2008 ¥u RTUALSCOPICS sow ore Move fe: Vialsco

  25. Slide 25: Adjusted EBITDA — Yearly Trend

    Adjusted EBITDA* — Yearly Trend Annual Adjusted EBITDA rong cost controls and f scale a VIRTUALSCOPICS

  26. Slide 26: Project Balance (Backlog)

    Project Balance (Backlog) as of - December 31,

  27. Slide 27: 2011 Financial Guidance

    2011 Financial Guidance Financial Area 2011 Guidance | Revenues | $16 million Full year gross margin | (ox relmbursed cost) ue | Full year Adjusted EBITDA | $1.7 million VIRTUALSCOPICS

  28. Slide 28: First Quarter 2011 Results

    First Quarter 2011 Results Financial Area $3,071k Operating Income | Gross Profit $1,600k | $1,598k Gross Margin | s rein 48% | 56% | R&D Expenditures | Stock Compensation Adjusted EBITDA

  29. Slide 29: Personalized Medicine Application

    a . we ¥ VIRTUALSCOPICS | Personalized Medicine Application

  30. Slide 30: Supporting Information

    Supporting Information Most treated patients are late stage. Waiting two months for determination of therapy efficacy could be fatal. Response rates of <30% drive the need for an early screening tool. Anti-angiogenic and vascular disruptive drugs target the newly formed blood vessels that tumor cell

  31. Slide 31: The Answer to Anti-Angiogenesis

    The Answer to Anti-Angiogenesis Effectiveness The only effective and proven Anti- response companion diagnostic approach Key Factors a ¥ VIRTUALSCOPICS

  32. Slide 32: Dynamic Contrast-Enhanced MRI

    Dynamic Contrast-Enhanced MRI (DC! Detect efficacy signal Baseline Day 2 Week 4 Week 8

  33. Slide 33: VirtualScopics DCE-MRI Companion Diagnostic Solution

    Vi p DCE-MRI C i Diagnostic Solution L Reasons to Consider PPV of other companion diagnostic. Pp ‘ection esued patent test in he market range from 60% fl creates a higher/stronger barre for (Her-2) to 80% (K-RAS) ‘others using similar technologies. vituatscoies nas conducted ow so aca ‘als using DCE

  34. Slide 34: Regulatory Process

    Regulatory Process 510k on application as a predictor of response to certain cancer therapies 510k on Collect additional application as an data to support image processing predictive nature tool of tool # Vint ALScOPICS Viealscopes AI Rights Reserved

  35. Slide 35: Pre-IDE package sent to the FDA

    Pre-IDE package sent to the FDA in February to confirm key elements of our first 510k submission, most importantly: VS Perfusion Software is Class | C Pred indicated for the post-image Absence of a suitable acquisition processing of Alternative is a predicate device would dynamic contrast-enhanced ‘

  36. Slide 36: Next steps

    Next steps ¢ File 510k ey the end of 2011 Continue to pursue partnership opportunities as a potential companion diagnostic tool and in support of FDA and Payer data requirements Develop relationships with key opinion leaders to assist in the collection of data and market option ° ViealScopes At Righ

  37. Slide 37: 2010 Capital Markets

    Yi virruaiscorics 2010 Capital Markets

  38. Slide 38: VSCP: 2010

    VSCP: 2010 ek ant L {Liss Taare 2 iA wil Viealscopes AI Rights Reserved # Vint ALScOPICS

  39. Slide 39: Market Outreach

    Market Outreach * Conference attendance * OneMed Place — San Francisco * Biolnvestor Conference — San Francisco * BioCEO — New York * Rodman & Renshaw — London * Rodman & Renshaw — New York * Added to the Russell 2000 * Two independent research analyst reports ViealScopes At Rights Reserved

  40. Slide 40: Thank You

    Thank You Question and Answer a \ VIRTUALSCOPICS ‘coin Viealscopes At Rights Reserved

  41. Slide 41: Meeting agenda: director election and auditor ratification

    Dan Kerpelman Robert Klimasewski Norman Mintz Charles Ph Terence We atify the appointment of Marcum LLP as independent financial statement auditors for the fiscal year ended December 31, 2011 OMT RTUALSCOPICS Brow mere Moe fv

  42. Slide 42: Thank You

    On behalf of the VirtualScopics’ Board of Directors and Employees Thank You Vu RTUALSCOPICS row ore Moves

VirtualScopics — Shareholder Meeting (May 2011) on 6ix